Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market [Yahoo! Finance Canada]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance Canada
CEO Bob Bradway shared a peek at phase II results of the potential competitor to market leaders Wegovy from Novo Nordisk ( NVO ) and Zepbound from Eli Lilly ( LLY ) during Amgen's earnings call late Thursday. "Following the interim analysis, I would say we're confident in MariTide's differentiated profile, and believe it will address important unmet medical needs," Bradway said. Bradway and other executives did not expand on what exactly would differentiate it from existing products, however. Final phase II results are expected later in the year and the company has yet to begin the final step toward approval, a phase III trial of the drug. Still, Novo's stock slid more than 1% and Lilly's fell nearly 3% Friday. But analysts caution more information is needed. ADVERTISEMENT "While the update is encouraging ... we will still need to see full [phase II] data in order to evaluate MariTide's potential role in the rapidly evolving obesity space," said JPMorgan analyst Chris Schot
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Succession drama grips Gucci as sales fail to make the cut [Yahoo! Finance]Yahoo! Finance
- Temedica Expands Its Advisory Board With Former Gematik CEO Markus Leyck Dieken [Yahoo! Finance]Yahoo! Finance
- Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/17/24 - Form 6-K
- 5/17/24 - Form SD
- 5/15/24 - Form 6-K
- NVO's page on the SEC website